ProMIS Neurosciences, Inc. (PMN)
| Market Cap | 81.88M +404.7% |
| Revenue (ttm) | n/a |
| Net Income | -40.62M |
| EPS | -13.36 |
| Shares Out | 8.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,373 |
| Open | 9.77 |
| Previous Close | 9.73 |
| Day's Range | 9.09 - 10.30 |
| 52-Week Range | 6.27 - 39.75 |
| Beta | -0.17 |
| Analysts | Strong Buy |
| Price Target | 35.28 (+286.42%) |
| Earnings Date | May 12, 2026 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PMN stock is "Strong Buy." The 12-month stock price target is $35.28, which is an increase of 286.42% from the latest price.
News
ProMIS Neurosciences Transcript: Jefferies Global Healthcare Conference 2026
A clinical-stage company presented its antibody platform targeting misfolded proteins in neurodegenerative diseases, highlighting strong finances, a fully enrolled Alzheimer's trial, and upcoming interim safety and biomarker data in early Q3. The lead asset aims to improve efficacy and safety, with top-line results expected early next year.
ProMIS Neurosciences to Participate in Upcoming Conferences in June
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfold...
ProMIS Neurosciences Transcript: AGM 2026
Annual meeting covered financials, board elections, auditor reappointment, and approval of a stock plan amendment. Key clinical milestones for PMN310 in Alzheimer's disease were highlighted, with major financing secured to support ongoing trials and development.
ProMIS Neurosciences initiated with a Buy at Brookline
Brookline initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $40 price target
ProMIS Neurosciences reports Q1 EPS ($1.26) vs. ($5.27) last year
Existing cash resources of $63.8M at quarter end are expected to fund planned operations through 2027, including the completion of the PRECISE-AD trial. “2026 has the potential to be a…
ProMIS Neurosciences Earnings release: Q1 2026
ProMIS Neurosciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
ProMIS Neurosciences Quarterly report: Q1 2026
ProMIS Neurosciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therape...
ProMIS Neurosciences Slides: Investor presentation
ProMIS Neurosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's dise...
ProMIS Neurosciences Proxy statement: Proxy filing
ProMIS Neurosciences filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
ProMIS Neurosciences Proxy statement: Proxy filing
ProMIS Neurosciences filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
ProMIS Neurosciences files $200M mixed securities shelf
17:24 EDT ProMIS Neurosciences (PMN) files $200M mixed securities shelf
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear...
ProMIS Neurosciences Annual report: Q4 2025
ProMIS Neurosciences has published its Q4 2025 annual report on March 25, 2026.
ProMIS Neurosciences Earnings release: Q4 2025
ProMIS Neurosciences released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
ProMIS Neurosciences Registration statement: Registration filing
ProMIS Neurosciences filed a registration statement on March 25, 2026, providing details about a securities offering with the SEC.
ProMIS Neurosciences files to sell 13.83M common shares for holders
The company will not receive any of the proceeds from sales of its securities by the selling securityholders pursuant to this prospectus.
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disea...
ProMIS Neurosciences Registration statement: Registration Filing
ProMIS Neurosciences filed a registration statement on March 18, 2026, providing details about a securities offering with the SEC.
ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Enrollment in a robust phase 1b Alzheimer's trial is complete, with interim and final data expected this year. The proprietary EpiSelect platform enables highly selective targeting of toxic oligomers, aiming for improved efficacy and safety. Strong financing and high retention support a pivotal year.
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas...
Promis Neurosciences Inc trading resumes
09:38 EST Promis Neurosciences (PMN) Inc trading resumes
Promis Neurosciences Inc trading halted, volatility trading pause
09:33 EST Promis Neurosciences (PMN) Inc trading halted, volatility trading pause
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-...